The primary objective of this study was to estimate the cost-effectiveness of nivolumab plus chemotherapy compared with chemotherapy alone as first-line treatment for advanced or metastatic PD-L1 CPS ≥5 GC/GEJC/esophageal adenocarcinoma patients from the perspective of the Chinese healthcare system. This evidence concerns the gene CD274 and esophageal adenocarcinoma.